Answers are grounded in this paper and cite their sources.
OVERVIEW:The task of bringing novel pharmaceutical products to market quickly at reasonable cost is daunting. While both pharmaceutical sales and R&D expenses are on the rise, the latter is outpacing the former. In order to increase top-line revenues, pharmaceutical firms have been employing a range of strategies to supplement the vitality of their R&D portfolios. While these strategies have the potential to increase revenues, they typically increase the demand for development resources that are already in short supply. Two models—steady-state and dynamic—allow R&D managers to estimate these resource requirements accurately and allocate them intelligently.
No takes yet. Share an insight, caveat, or question.
Bunch et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: